1-Dimethylaminomethyl-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1-Dimethylaminomethyl-LSD is a lysergamide derivative related to the psychedelic drug lysergic acid diethylamide (LSD).[1][2][3][4][5] It was synthesized and described by Albert Hofmann and Franz Troxler at Sandoz in 1957.[1][3][4][5] According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), 1-dimethylaminomethyl-LSD has been limitedly described, and it is unknown whether it was ever tested in humans.[1] The 2-dimethylaminomethyl-LSD positional isomer has also been described, and was found to have 18.5% of the antiserotonergic activity of LSD in vitro.[6]
Other names1-Dimethylaminomethyl-N,N-diethyllysergamide; 1-[(Dimethylamino)methyl]-N,N-diethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
ATC code
- None
FormulaC23H32N4O
Molar mass380.536 g·mol−1
| Clinical data | |
|---|---|
| Other names | 1-Dimethylaminomethyl-N,N-diethyllysergamide; 1-[(Dimethylamino)methyl]-N,N-diethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C23H32N4O |
| Molar mass | 380.536 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- Substituted lysergamide
- OML-632 (1-hydroxymethyl-LSD)
- MLD-41 (1-methyl-LSD)
- ALD-52 (1-acetyl-LSD)